STERIS Share Repurchase Program, Remaining Authorized, Amount decreased by 25.0% to $150.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $300.00M to $150.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
A high remaining balance indicates potential future support for the stock price through buybacks.
This is the portion of the board-authorized share repurchase program that has not yet been executed. It indicates the re...
Used by investors to gauge the near-term potential for share count reduction and capital return.
other_stock_repurchase_program_remaining_authorized_repu_889179| Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|
| Value | $443.88M | $400.00M | $300.00M | $300.00M | $200.00M | $150.00M |
| QoQ Change | — | -9.9% | -25.0% | +0.0% | -33.3% | -25.0% |
| YoY Change | — | — | — | -32.4% | -50.0% | -50.0% |